Meridian Medical Technologies, Inc., a Pfizer company, has introduced a new single-vial dose of CYANOKIT (hydroxocobalamin for injection) 5 g
First identified and characterized by researchers at the University of Zagreb, BPC-157 has been the subject of extensive preclinical investigation spanning over two decades
Research Considerations Across the preclinical literature, BPC-157 is consistently described as well tolerated with no established lethal dose in animal toxicology, and injection-site reactions among the few commonly noted effects
This conservative approach means patients often spend weeks simply waiting for natural healing to occur
NICE guidelines for weight management emphasise evidence-based interventions including dietary modification, increased physical activity, behavioural therapy, and in appropriate cases, pharmacological treatments (such as orlistat or semaglutide) or bariatric surgery